Haemonetics has delivered four consecutive quarterly earnings beats with estimates trending higher and converts cash at more than three times reported net income, but the stock has essentially reached its near-term price target — leaving only 4.5% of upside against a 7% defined downside at a 0.64-to-1 reward-to-risk ratio — while supply-chain concentration in key components adds an idiosyncratic risk that limits conviction.
Thesis pillars
- Consistent Earnings Execution→Stable
- Exceptional Cash Conversion Quality→Stable
- Price At Target Thin Upside→Stable
- +1 more pillar — see the Why tab for full reasoning
Haemonetics Corporation (HAE) Stock Analysis
Healthcare · Medical Devices
Sell if holding. At $75.07, A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: apheresis equipment from Asia; Concentration risk — Supplier: Tetakawi.
Haemonetics develops and sells medical technology systems across three segments: Hospital (44.1% of FY2026 revenue), Plasma (39.3%), and Blood Center (16.6%), serving hospitals, biopharmaceutical companies, and blood and plasma collectors in approximately 90 countries. The ten... Read more
Sell if holding. At $75.07, A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: apheresis equipment from Asia; Concentration risk — Supplier: Tetakawi. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
About Haemonetics Corporation
About Haemonetics Corporation
Haemonetics' Hospital segment — VASCADE vascular closure devices, the TEG 6s hemostasis system, Cell Saver Elite+, and SavvyWire — generated 44.1% of FY2026 net revenues, with Plasma (NexSys PCS, NexLynk DMS) at 39.3% and Blood Center at 16.6%. In Q4 FY2026, the company received FDA 510(k) clearance for NexSys PCS with Persona PLUS technology and FDA approval to expand the VASCADE MVP XL indication to larger-bore sheaths. Products reach approximately 90 countries through a direct sales force and independent distributors across roughly 87 markets; the top-ten customers generated approximately 44% of net revenues, with one Plasma customer at 13%.
Haemonetics generates revenue through device sales and related single-use disposables, with the recurring disposable component providing volume visibility tied to plasma donation and procedure rates. The Plasma segment serves a small pool of vertically integrated biopharmaceutical customers — including Grifols S.A., Octapharma AG, Takeda's BioLife Plasma subsidiary, and CSL — that operate dedicated collection centers and demand yield improvements that lower per-unit collection costs. In January 2025, the company divested the Whole Blood product line within Blood Center, concentrating resources in Plasma and Hospital. The Hospital segment competes for value analysis committee approvals for VASCADE devices, where price-point sensitivity relative to manual compression alternatives exposes the company to budget pressure from integrated delivery networks and group purchasing organizations. The PerQseal Elite large-bore closure system has a premarket approval application currently under FDA review for an arterial indication in the United States.
Show full overview
Haemonetics faces concentrated manufacturing dependencies across its product lines. The company sources all of its apheresis equipment from Asia — a single-region supply chain that exposes operations to tariff disruptions, geopolitical events, or logistics failures affecting a core Plasma and Blood Center input. For VASCADE vascular closure devices, Haemonetics manufactures under a shelter plan service agreement with Tetakawi in Guaymas, Mexico, relying on Tetakawi for facility security, manufacturing personnel, recruiting, government compliance, and cross-border shipping. Additionally, the company relies on a single third-party vendor for several business processes including customer service, enterprise technology, procurement, and human resources — a single-source dependency that could disrupt operations if the vendor fails or terminates the relationship.
See also: Healthcare · Medical Devices
From Haemonetics Corporation's most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-07-06Recent Developments — Haemonetics Corporation
Latest news
- NEWS Chiesi strikes $1.9B deal for KalVista and its oral HAE therapy - FirstWord Pharma — FirstWord Pharma positive
- NEWS BioCryst (BCRX) Is Up 11.7% After New HAE Data Spotlight ORLADEYO And Navenibart Potential - simplywall.st — simplywall.st positive
- NEWS Haemonetics Earnings: What To Look For From HAE - StockStory — StockStory neutral
- NEWS Haemonetics Earnings: What To Look For From HAE - FinancialContent — FinancialContent neutral
- NEWS NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA - The Globe and Mail — The Globe and Mail neutral
Generated 2026-07-06T05:40:27Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomertop ten customers44%10-K Item 1: 'our ten largest customers accounted for approximately 44% of our net revenues'
- LOWCustomerone Plasma customer13%10-K Item 1: 'one Plasma customer accounted for approximately 13% of total net revenues'
- HIGHSupplierapheresis equipment from Asia10-K Item 1A: 'We source all of our apheresis equipment from Asia'
- HIGHSupplierTetakawi10-K Item 1A: 'we manufacture our VASCADE vascular closure devices under a shelter plan service agreement with Offshore International Incorporated (d/b/a Tetakawi)'
- HIGHSuppliersingle third-party vendor10-K Item 1A: 'we rely on a single vendor to support several of our business processes, including customer service and support and elements of enterprise technology'
Material Events(8-K, last 90d)
- 2026-05-01Item 5.02LOWCharles J. Dockendorff will not stand for re-election at 2026 Annual Meeting of Shareholders. Has served as director since 2014, currently on Audit Committee and Governance and Compliance Committee. Decision not the result of any disagreement with the company.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $75.07, A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: apheresis equipment from Asia; Concentration risk — Supplier: Tetakawi. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $69.82. Score 5.2/10, moderate confidence.
Take-profit target: $80.35 (+7.0% upside). Prior stop was $69.82. Stop-loss: $69.82.
Concentration risk — Supplier: apheresis equipment from Asia; Concentration risk — Supplier: Tetakawi; Analyst target reached - limited upside remaining.
Haemonetics Corporation trades at a P/E of 36.6 (forward 13.0). TrendMatrix value score: 6.0/10. Verdict: Sell.
15 analysts cover HAE with a consensus score of 4.1/5. Average price target: $85.
What does Haemonetics Corporation do?Haemonetics develops and sells medical technology systems across three segments: Hospital (44.1% of FY2026 revenue),...
Haemonetics develops and sells medical technology systems across three segments: Hospital (44.1% of FY2026 revenue), Plasma (39.3%), and Blood Center (16.6%), serving hospitals, biopharmaceutical companies, and blood and plasma collectors in approximately 90 countries. The ten largest customers represented approximately 44% of FY2026 net revenues, with one Plasma customer alone accounting for approximately 13%.